Pretty much an immediate dismissal for me for JAV.
Why is this stock a value stock?
From the article, it's not because of the balance sheet or earnings, but rather because of the favorable prospects the author and the ceo believe for Dyloject.
So for me to buy this stock, even in my small spec plays, I have to believe in Dyloject, maybe even be an expert in it, or else I have to believe in others who belive in it - the ceo and/or the article author.
Irks me when author states, "So, why the recent decline in stock price? The simple answer is, impatient investors who waited a couple months since the August conference call and when no deal was made, sold their stock."
Confusing speculators/market players/investors. Investors almost by definition are patient. And "investors", here, would have to be people who've carefully considered the situation and determined the stock offers safety of principal and an adequate return.
Hard for me to see that with this company/stock info. provided.
Of course that doesn't mean the drug won't be a roaring success or that the stock won't go from $1.60 to $16. If it does though, it'll most likely be without me.
Perhaps I am missing something about JAV. A/o now though, with my quick look, I pass. |
